After assessing safety and immunogenicity in phase 1/2 clinical trials, NVX-CoV2373 is currently in two pivotal phase 3 studies to evaluate vaccine efficacy, safety and immunogenicity. 

NVX-CoV2373 clinical trials have enrolled more than 30,000 volunteers around the globe. Learn more about our clinical trial enrollment and progress toward diversity demographics.

Aug 4, 2022
COVID-19

Novavax Announces Initiation of Phase 2b/3 Hummingbird™ Global Clinical Trial for the Novavax COVID-19 Vaccine in Children Aged Six Months Through 11 Years

Aug 1, 2022
Statement
COVID-19

Novavax Statement on U.S. Vaccinations with the Novavax COVID-19 Vaccine, Adjuvanted Underway

Jul 26, 2022
COVID-19

Novavax Announces Expanded Approval of Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 through 17 in Japan

Jul 26, 2022
COVID-19

Novavax Nuvaxovid™ COVID-19 Vaccine Granted Provisional Registration in Australia for Use in Adolescents Aged 12 Through 17

Jul 22, 2022
Statement
COVID-19

Novavax Statement on U.S. Availability of the Novavax COVID-19 Vaccine, Adjuvanted

Jul 19, 2022
Statement
COVID-19

U.S. Centers for Disease Control and Prevention Endorses Advisory Committee on Immunization Practices’ Recommendation for Novavax COVID-19 Vaccine, Adjuvanted

Jul 19, 2022
COVID-19

U.S. CDC Advisory Committee Unanimously Recommends Novavax COVID-19 Vaccine, Adjuvanted as a Primary Series for Individuals Aged 18 and Older

Jul 19, 2022
COVID-19

Novavax Announces Expanded Agreement with SK bioscience to Manufacture COVID-19 Vaccine Containing Omicron Variant and Manufacture the Novavax COVID-19 Vaccine in Prefilled Syringes

Jul 15, 2022
Statement
COVID-19

Novavax COVID-19 Vaccine to be Reviewed at U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices Meeting on July 19, 2022

Jul 14, 2022
Statement
COVID-19

Novavax Statement on European Medicines Agency Nuvaxovid™ Label Update Related to Allergic Reaction

Highlights

Visit our global authorization website

Our commitment to equitable access and transparency

Announcement of UK and South Africa trial results

Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK phase 3 trial

PREVENT-19 fact sheet

Background information on PREVENT-19, Novavax pivotal phase 3 trial

Showper page